Advocacy News

On May 11, 2015, CDF CEO Marilyn G. Geller was proud to represent the celiac community at the public meeting of the U.S. Food and Drug Administration Functional GI Patient-Focused…

On May 11, 2015, the Food and Drug Administration (FDA) will conduct a public meeting on Functional GI Disorders Patient-Focused Drug Development. Celiac Disease Foundation was requested by the FDA to provide commentary about the impact of celiac disease on patients’ daily lives, the types of treatment benefit that matter most to patients, and patients’ perspectives on the adequacy of the available therapies.

CDF CEO, Marilyn Geller, will present the celiac patient voice at the May 11 FDA Patient-Focused Drug Development meeting. Have your voice be heard. Complete the CDF Celiac PFDD Survey now.

Celiac Disease Foundation Chief Executive Officer, Marilyn Geller, attended The State of Autoimmune Disease: A National Summit at the National Press Club in Washington, D.C. The Summit explored the current trends in diagnosis, treatment, and therapies, presented by experts in research, environment, advocacy, and patient issues.

On March 30-31st, 2015, Celiac Disease Foundation Chief Executive Officer, Marilyn G. Geller, attended the FDA Public Workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3) near Washington,…